
|Articles|December 1, 2004
Galderma R&D facility underscores commitment
Sophia Antipolis, France - Galderma's commitment to dermatology, and dermatology only, is nowhere more evident than in its sprawling, approximately 24,000-square-foot research and development facility in the south of France.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















